Racura Oncology Says First Patient Recruited to Phase 1 HARNESS-1 Cancer Drug Trial

MT Newswires Live

Mar 31

Racura Oncology (ASX:RAC) said the first patient was recruited to its phase 1 HARNESS-1 clinical trial of its cancer drug candidate RC220 in patients with non-small cell lung cancer with activated epidermal growth factor receptor (EGFR) mutations being treated with osimertinib, according to a Tuesday Australian bourse filing.

The company said the trial aims to address the significant unmet medical need of preventing or delaying resistance to standard-of-care EGFR-mutant tyrosine kinase inhibitors such as osimertinib, with four additional clinical trial sites expected to be activated in the coming months.

RC220 is an experimental oral drug candidate designed to inhibit the proto-oncogene tyrosine-protein kinase (SRC) protein, which is believed to drive resistance to EGFR-targeted therapies.

The trial aims to test whether combining RC220 with osimertinib can prevent or delay tumors from developing resistance to the standard-of-care treatment, the filing added.

The company's shares rose 2% in recent Tuesday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2623723443"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2623723443\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2623723443?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 12:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623723443","market":"nz","top_or_hot":-1,"title":"Racura Oncology Says First Patient Recruited to Phase 1 HARNESS-1 Cancer Drug Trial","media":"MT Newswires Live","content":"<html><body><p> Racura Oncology (ASX:RAC) said the first patient was recruited to its phase 1 HARNESS-1 clinical trial of its cancer drug candidate RC220 in patients with non-small cell lung cancer with activated epidermal growth factor receptor (EGFR) mutations being treated with osimertinib, according to a Tuesday Australian bourse filing.</p><p>The company said the trial aims to address the significant unmet medical need of preventing or delaying resistance to standard-of-care EGFR-mutant tyrosine kinase inhibitors such as osimertinib, with four additional clinical trial sites expected to be activated in the coming months.</p><p>RC220 is an experimental oral drug candidate designed to inhibit the proto-oncogene tyrosine-protein kinase (SRC) protein, which is believed to drive resistance to EGFR-targeted therapies.</p><p>The trial aims to test whether combining RC220 with osimertinib can prevent or delay tumors from developing resistance to the standard-of-care treatment, the filing added.</p><p>The company's shares rose 2% in recent Tuesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Racura Oncology Says First Patient Recruited to Phase 1 HARNESS-1 Cancer Drug Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRacura Oncology Says First Patient Recruited to Phase 1 HARNESS-1 Cancer Drug Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-31 12:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Racura Oncology (ASX:RAC) said the first patient was recruited to its phase 1 HARNESS-1 clinical trial of its cancer drug candidate RC220 in patients with non-small cell lung cancer with activated epidermal growth factor receptor (EGFR) mutations being treated with osimertinib, according to a Tuesday Australian bourse filing.</p><p>The company said the trial aims to address the significant unmet medical need of preventing or delaying resistance to standard-of-care EGFR-mutant tyrosine kinase inhibitors such as osimertinib, with four additional clinical trial sites expected to be activated in the coming months.</p><p>RC220 is an experimental oral drug candidate designed to inhibit the proto-oncogene tyrosine-protein kinase (SRC) protein, which is believed to drive resistance to EGFR-targeted therapies.</p><p>The trial aims to test whether combining RC220 with osimertinib can prevent or delay tumors from developing resistance to the standard-of-care treatment, the filing added.</p><p>The company's shares rose 2% in recent Tuesday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2623723443","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623723443","pubTimestamp":1774930126,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Racura Oncology  said the first patient was recruited to its phase 1 HARNESS-1 clinical trial of its cancer drug candidate RC220 in patients with non-small cell lung cancer with activated epidermal growth factor receptor  mutations being treated with osimertinib, according to a Tuesday Australian bourse filing.The company said the trial aims to address the significant unmet medical need of preventing or delaying resistance to standard-of-care EGFR-mutant tyrosine kinase inhibitors such as osimertinib, with four additional clinical trial sites expected to be activated in the coming months.RC220 is an experimental oral drug candidate designed to inhibit the proto-oncogene tyrosine-protein kinase  protein, which is believed to drive resistance to EGFR-targeted therapies.The trial aims to test whether combining RC220 with osimertinib can prevent or delay tumors from developing resistance to the standard-of-care treatment, the filing added.The company's shares rose 2% in recent Tuesday trad","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","BK7508":"医药生物股","BK4231":"零售房地产信托","BK4080":"零售业房地产投资信托","SRC":"Spirit Realty Capital","RAC.AU":"RACE ONCOLOGY LTD"},"translate_title":"Racura Oncology表示招募了第一名患者参加HARNESS-1癌症药物1期试验","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RAC.AU":1,"SRC":1},"content_text":"Racura Oncology (ASX:RAC) said the first patient was recruited to its phase 1 HARNESS-1 clinical trial of its cancer drug candidate RC220 in patients with non-small cell lung cancer with activated epidermal growth factor receptor (EGFR) mutations being treated with osimertinib, according to a Tuesday Australian bourse filing.The company said the trial aims to address the significant unmet medical need of preventing or delaying resistance to standard-of-care EGFR-mutant tyrosine kinase inhibitors such as osimertinib, with four additional clinical trial sites expected to be activated in the coming months.RC220 is an experimental oral drug candidate designed to inhibit the proto-oncogene tyrosine-protein kinase (SRC) protein, which is believed to drive resistance to EGFR-targeted therapies.The trial aims to test whether combining RC220 with osimertinib can prevent or delay tumors from developing resistance to the standard-of-care treatment, the filing added.The company's shares rose 2% in recent Tuesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}